Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin

References

• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care. 2010;16( 7 suppl):S187–S194
   PubMed Web of Science ®Google Scholar
• . Blech S, Ludwig—Schwellinger E, Grafe—Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667–678
   PubMed Web of Science ®Google Scholar
• . Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32( suppl 2):S253–S259
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559
   PubMed Web of Science ®Google Scholar
• . Phillips PJ, Twigg SM. Oral hypoglycaemics—a review of the evidence. Aust Fam Physician. 2010;39(9):651–653
   PubMed Web of Science ®Google Scholar
• . Jorgensen CH, Gislason GH, Andersson C, . Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention—a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54
   PubMed Web of Science ®Google Scholar
• . Devineni D, Morrow L, Hompesch M, . Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6): 539–545
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin [abstract]. Diabetes. 2010;59( suppl 1):A21. Abstract 0077-OR
   Google Scholar
• . Sha S, Devineni D, Ghosh A, . Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]. Diabetes. 2010;59 ( suppl 1):A155. Abstract 0568-P
   Google Scholar
• . National Institutes of Health. National diabetes statistics. National Diabetes Information Clearinghouse website. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed May 29, 2011
   Google Scholar
• . Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875–883
   PubMed Web of Science ®Google Scholar
• . Abdul—Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782–790
   PubMedGoogle Scholar
• . Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794
   PubMed Web of Science ®Google Scholar
• . Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. Philadelphia, PA: Elsevier Inc; 2006
   Google Scholar
• . Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8): 1279–1284
   PubMed Web of Science ®Google Scholar
• . Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–141
   PubMed Web of Science ®Google Scholar
• . Chen J, William S, Ho S, . Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57–92
   PubMedGoogle Scholar
• . Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992;263(3 pt 2):F459–F465
   PubMedGoogle Scholar
• . Freitas HS, Anhe GF, Melo KF, . Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149(2):717–724
   PubMed Web of Science ®Google Scholar
• . Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434
   PubMed Web of Science ®Google Scholar
• . White J. Apple trees to sodium glucose cotransproter inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28(1):5–10
   Google Scholar
• . Achard C, Delamare V. The bark of the apple root, phlorizin, reduces diabetic hyperglycemia. Soc Medic Des Hopitaux. 1899:379–393
   Google Scholar
• . Oku A, Ueta K, Arakawa K, . T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794–1800
   PubMed Web of Science ®Google Scholar
• . Katsuno K, Fujimori Y, Takemura Y, . Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320(1):323–330
   PubMed Web of Science ®Google Scholar
• . Fujimori Y, Katsuno K, Ojima K, . Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009; 609(1–3):148–154
   PubMed Web of Science ®Google Scholar
• . Fujimori Y, Katsuno K, Nakashima I, Ishikawa—Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327(1):268–276
   PubMed Web of Science ®Google Scholar
• . Jabbour SA. The importance of reducing hyperglycemia while preserving insulin secretion—the rationale for sodium-coupled glucose co-transporter 2 inhibition in diabetes. US Endocrinology. 2009;5(1):75–78
   Google Scholar
• . Meng W, Ellsworth BA, Nirschl AA, . Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008; 51(5):1145–1149
   PubMed Web of Science ®Google Scholar
• . Obermeier M, Yao M, Khanna A, . In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405–414
   PubMed Web of Science ®Google Scholar
• . Bellamine A, Smarsh M, Onorato J, . Dapagliflozin (BMS-512148) is a competitive, selective and reversible inhibitor of human SGLT2. Presented at: BioMedical Transporters; August 9, 2009; Thun, Switzerland
   Google Scholar
• . Uveges A, Hagan D, Onorato J, . Dapagliflozin selectively inhibits human SGLT2 versus SGLT1, SMIT1, SGLT4, and SGLT6. Presented at: American Diabetes Association 71st Scientific Sessions; June 24–28, 2011; San Diego, CA. Poster P-987
   Google Scholar
• . Poucher SM, DeSchoolmeester J, Ehenborn J, Vernon W, Clementz T. Dapagliflozin selectivity for glucose transporters GLUT1, 2, and 4. Presented at: American Diabetes Association 71st Scientific Sessions; June 24–28, 2011; San Diego, CA. Poster P-1041
   Google Scholar
• . Bristol Myers-Squibb, AstraZeneca. US Food and Drug Administration Endocrinologic and Metabolic Advisory Committee background document: dapagliflozin, BMS-512148, NDA 202293. US Food and Drug Administration. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/ucm262993.htm. Accessed July 20, 2011
   Google Scholar
• . Han S, Hagan DL, Taylor JR, . Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729
   PubMed Web of Science ®Google Scholar
• . Zinker B, Ma X, Liu H, . Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats [abstract]. Diabetes. 2011;60( suppl 1):A283. Abstract 1031-P
   Google Scholar
• . Macdonald FR, Peel JE, Jones HB, . The novel SGLT2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12(11): 1004–1012
   PubMed Web of Science ®Google Scholar
• . Jurczak MJ, Lee HY, Birkenfeld AL, . SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890–898
   PubMed Web of Science ®Google Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513–519
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract]. Diabetes. 2011;60( suppl 1):A271. Abstract 988-P
   Google Scholar
• . Nauck MA, Del PS, Meier JJ, . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022
   PubMed Web of Science ®Google Scholar
• . Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results [abstract]. Presented at: American Diabetes Association 71st Scientific Sessions; June 24–28, 2011; San Diego, CA. Abstract 40-LB
   Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–456
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight grain with low incidence of hypoglycemia in type 2 diabetes. [abstract]. Diabetes. 2011;60( suppl 1):A270. Abstract 986-P
   Google Scholar
• . Strojek K, Yoon KH, Hruba B, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–938
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, ; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy—efficacy of a novel insulin-independent treatment [abstract]. Diabetes. 2010;59( suppl 1):A21–A22. Abstract 78-OR
   Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin [abstract]. Diabetes. 2010;59( suppl 1):LB7. Abstract 21-LB
   Web of Science ®Google Scholar
• . Yu PC, Bosnyak Z, Ceriello A. The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;89(1):1–9
   PubMedGoogle Scholar
• . Salsali A, Hruba V, Ying L, . Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract]. Diabetes. 2011;60( suppl 1):A286. Abstract 1104-P
   Google Scholar
• . Salsali A, Bastien A, Mansfield T, Ying L, Ravichandran S, List J. Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus. Presented at: American Association of Clinical Endocrinologists 19th Annual Meeting and Clinical Congress; April 21–25, 2010; Boston, MA
   Google Scholar
• . Kasichayanula S, Liu X, Shyu WC, . Lack of pharmacokinetic interaction between dapagliflozin, a novel SGLT2 inhibitor, and metformin, pioglitazone, glimepiride, or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47–54
   PubMed Web of Science ®Google Scholar
• . Kasichayanula S, Chang M, Liu X, . Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163–177
   PubMed Web of Science ®Google Scholar
• . Wilcox CS, Liu X, Kasichayanula S, . Evaluation of interactions of dapagliflozin and bumetanide. Presented at: American Society of Nephrology; November 16–21, 2010; Denver, CO
   Google Scholar
• . Rohwedder K, Hruba V, Salsali A, . Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has a low propensity to cause hypoglycemia in patients with type 2 diabetes [abstract]. Diabetes. 2011;60( suppl 1):A286. Abstract 1042-P
   Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy [published online ahead of print March 23, 2010]. Diabetes Care.
   Google Scholar
• . Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9): 1656–1662
   PubMed Web of Science ®Google Scholar
• . Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes. 2011;60( suppl 1):A270. Abstract 984-P
   Google Scholar
• . List JF, Ley S, Ptaszynska A, . Characterization of genital infections in the setting of pharmacologically-induced glucosuria [abstract]. Diabetes. 2011;60( suppl 1):A270. Abstract 985-P
   Google Scholar
• . Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–1123
   PubMed Web of Science ®Google Scholar
• . Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–2823
   PubMed Web of Science ®Google Scholar
• . Ptaszynska A, Johnsson K, Apanovitch AM, Sugg JE, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for T2DM. Presented at: American Diabetes Association; June 8–12, 2012; Philadelphia, PA
   Google Scholar
• . Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol. 2005;16( suppl 1):S18–S21
   PubMedGoogle Scholar
• . Henry R, Murray A, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM [abstract]. Diabetes. 2011;60( suppl 1):A84. Abstract 307-OR
   Google Scholar
• . Strojek K, Hruba V, Elze M, . Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy [abstract]. Diabetologia. 2010;53:S347. Abstract 870-P
   Google Scholar